Astrazeneca Ab

Xenon Pharmaceuticals Inc.

Eolas Therapeutics, Inc.

Steven Sigmund Wesolowski

Phil Edwards

Christoph Martin Dehnhardt

Theodore M Kamenecka

Qi Jia

Thilo Focken

Michael Edward Grimwood

Michael Scott Wilson

Jean-Christophe Andrez

Kristen Nicole Burford

Yuanjun He

Verner Alexander Lofstrand

Shaoyi Sun

Michael H Wood

Ashokkumar Bhikkappa Shenvi

Alla Yurevna Zenova

Andrew Griffin

Roland W Bürli

Dean Brown

Scott Throner

Jörg Holenz

Denis Labrecque

Todd Andrew Brugel

James Arnold

James Hulsizer

Thierry Groblewski

Dan Widzowski

James R Damewood

James Campbell Muir

M Edward Pierson, Jr

Roland Bürli

Roland Burli

Jorg Holenz

The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.

Halo-substituted piperidines as orexin receptor modulators

This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents

This invention is directed to heteroaryl-substituted sulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors

Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.

Cyclopropyl amide derivatives

Compounds the following formula: wherein Z is as described in the specification, pharmaceutically acceptable salts thereof, compositions comprising the same, and methods of treating bipolar disorder, an anxiety disorder, a mood disorder or schizophrenia or other psychotic disorder with said compounds.

Dibenzothiazepine derivatives and uses thereof&#x2014;424

Growing community of inventors

Natick, MA, United States of America

Steven Sigmund Wesolowski